Navigation Links
InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
Date:1/5/2012

patients treated with Esbriet in CAPACITY, and both were directionally higher than in patients receiving placebo in CAPACITY.

With these new analyses, this is the third InterMune study to show similar changes in lung function following slightly more than one year of Esbriet therapy. A fourth study from Japan demonstrated that pirfenidone reduces decline in lung function at one year.   

Additional details of the RECAP analyses will be presented on the conference call and webcast InterMune will host at 8:30 a.m. EST this morning.

Phase 3 ASCEND Study

InterMune today reported that patient enrollment in the Phase 3 pirfenidone study, ASCEND, in the United States and certain additional territories is expected to be fully enrolled in the second quarter of 2012.

  • ASCEND is a double-blind, placebo-controlled trial of 52 weeks duration with a primary endpoint of change in FVC between baseline and Week 52.  The trial will enroll approximately 500 IPF patients with mild-to-moderate impairment in lung function.
  • InterMune expects that results from the study will be available in mid-2013. 

 

Guidance for 2011 Expenses

The company updated its financial guidance for operating expenses in 2011:

  • R&D expense: anticipated to be in a range of approximately $75 to $80 million, previously estimated during InterMune's Third Quarter 2011 earnings call to be in the range of $85 to $95 million.
  • SG&A expense: anticipated to be in a range of approximately $85 to $90 million, previously projected during InterMune's Third Quarter 2011 earnings call to be in the range of $75 to $85 million. 
  • Total Operating Expenses (R&D and SG&A): anticipated to be in a range of approximately $160 to $170 million, compared to the previously projecte
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. InterMune Appoints Angus C. Russell to Board of Directors
2. InterMune to Release Third Quarter Financial Results on November 3
3. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
4. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
5. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
6. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
7. InterMune to Present at J.P. Morgan Healthcare Conference
8. InterMune Reports Third Quarter 2010 Financial Results
9. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
10. InterMune to Release Second Quarter Financial Results on July 27
11. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a biopharmaceutical ... that David J. Haen , Vice President, Business ... Biotech Industry Conference on Friday, September 26 th at ... at the Millennium Broadway Hotel in New ... archived webcast of the presentation will be available on ...
(Date:9/19/2014)... -- PCI is pleased to announce it has acquired ... provider of Clinical Trial Services and Temperature Controlled ... in the United Kingdom ... in the UK/EU to support global investigational studies ... distribution capacity, as well as consultative services for ...
(Date:9/18/2014)... 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... of the underwriters, option to purchase 675,000 additional ... company,s previously announced public offering of 4,500,000 shares ... being offered by Aratana Therapeutics.  With the exercise ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3PCI Announces Acquisition Of Biotec 2PCI Announces Acquisition Of Biotec 3PCI Announces Acquisition Of Biotec 4PCI Announces Acquisition Of Biotec 5PCI Announces Acquisition Of Biotec 6Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2
(Date:9/20/2014)... The Arizona Advanced Manufacturing Institute ... Manufacturing Day by opening its doors to the community. ... manufacturing labs will be offered between 10 a.m. and ... and Dobson campus (1833 W. Southern Ave, Mesa, AZ ... The AzAMI at MCC was established in the fall ...
(Date:9/19/2014)... Columbus, OH (PRWEB) September 20, 2014 ... Philadelphia Court of Common Pleas where a meeting took ... Risperdal side-effects complaints pending in the court’s mass ... scheduled to meet this past week at the Complex ... complaints are consolidated for pretrial proceedings. The Risperdal lawsuits ...
(Date:9/19/2014)... BearCom, a nationwide provider of wireless ... role played by instant, one-to-one and one-to-many communications ... , “In healthcare, speed of information flow ... emergency situations, can save precious seconds that can ... Hugh Johnston, Product & Purchasing Manager at BearCom. ...
(Date:9/19/2014)... working with The Melanoma Genetics Consortium, GenoMEL, an international ... Journal of the National Cancer Institute that ... "For the first time, we have established that the ... part in the risk of developing melanoma," said lead ... Medicine at the University of Leeds (UK). , ...
(Date:9/19/2014)... News) -- Your brain structure could help predict how willing ... Researchers at Yale University found those with greater volume ... cortex may be more likely to engage in risky behavior ... The study, funded by the U.S. National Institute on Aging, ... in the Northeast. The researchers sought to determine how brain ...
Breaking Medicine News(10 mins):Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4Health News:Melanoma risk found to have genetic determinant 2Health News:Brain Structure Might Help Predict Risky Behavior 2
... bundles, scientists say , , WEDNESDAY, April 15 (HealthDay News) ... in certain neural pathways of the brain to the ... finding could lead to a better understanding of the ... and coordination that characterizes this difficult-to-diagnose disorder -- also ...
... MD, April 14, 2009 -- Sleep is such an essential ... of our lives doing it -- some more successfully than ... United States and are a major cause of disease and ... risk of heart attack, stroke, hypertension, obesity, depression, and accidents. ...
... with 100% of Updated Interoperability RequirementsTAMPA, Fla., April ... provider of electronic health records, today announced that ... has approved Sage,s product, Sage Intergy EHR, ... EHR , additionally certified for Child ...
... Harvard Business School recently completed a case study ... a private nonprofit organization that helps children and families ... a national leader in the field of children,s behavioral ... Allen Grossman, Catherine Ross of the HBS Global Research ...
... AIDS for years after initial infection by HIV have ... One component of this remarkable resistance comes from an ... genes that help the immune system recognize and fight ... the Emory Vaccine Center studying HIV-infected people with particularly ...
... minimally invasive surgical approach to treat stomach cancer has ... a preferable treatment for some patients. , A new ... (MSKCC) compares traditional "open" surgery to remove the stomach ... which the surgeon removes the stomach while guided by ...
Cached Medicine News:Health News:Brain Scans Reveal Secrets of 'Writer's Cramp' 2Health News:New way to analyze sleep disorders 2Health News:New way to analyze sleep disorders 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 2Health News:Sage Intergy EHR Receives 08 CCHIT Certification 3Health News:Sage Intergy EHR Receives 08 CCHIT Certification 4Health News:Sage Intergy EHR Receives 08 CCHIT Certification 5Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 2Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 3Health News:Harvard Business School Publishes Case Study on Youth Villages-Intercept in Texas 4Health News:HIV handicaps itself to escape immune system pressure 2Health News:New minimally invasive surgery option for patients with stomach cancer 2
This unique hemostatic seal provides a simple option for beating heart CABG anastomoses, allowing you to use your own hand-suturing technique without the release of cerebral emboli associated with th...
... is a supportive .035" guide wire compatible stent system ... lengths of 18 mm, 28 mm, 38 mm and ... in 12 and 16 mm lengths. The 4.0 ... Two "diameter specific" OMNILINK® stents were developed - one ...
... particular challenge in transseptal left heart catheterization ... be exchanged for a sheath with an ... position. Traditionally, such an exchange has required ... patient. Biosense Webster has overcome this problem ...
... Jude Medical's line of guiding introducers ... RAMP, and 2 piece steerable, all ... catheters when the varying curves and ... physician technique. St. Jude Medical guiding ...
Medicine Products: